公开(公告)号：US20160009777A1

公开(公告)日：2016-01-14

申请号：US14864256

申请日：2015-09-24

申请人： ZEALAND PHARMA A/S

发明人： Jakob Lind TOLBORG ,  Keld FOSGERAU ,  Pia NØRREGAARD ,  Rasmus JUST ,  Ditte RIBER ,  Dieter Wolfgang HAMPRECHT ,  Robert AUGUSTIN ,  Leo THOMAS ,  Wolfgang RIST

IPC分类号： C07K14/605 ,  A61K45/06 ,  A61K38/26

CPC分类号： C07K14/605 ,  A61K38/26 ,  A61K45/06

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

公开(公告)号：US20190055296A1

公开(公告)日：2019-02-21

申请号：US15983822

申请日：2018-05-18

申请人： Zealand Pharma A/S

发明人： Jakob Lind TOLBORG ,  Keld FOSGERAU ,  Pia NØRREGAARD ,  Rasmus JUST ,  Ditte RIBER ,  Dieter Wolfgang HAMPRECHT ,  Robert AUGUSTIN ,  Leo THOMAS ,  Wolfgang RIST

IPC分类号： C07K14/605 ,  A61K38/26 ,  A61K45/06

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.